Technology Introduction Contract Signed for INV-008 (15-PGDH Inhibitor)
Signed exclusive worldwide license and co-development contract for INV-008, a 15-PGDH inhibitor targeting IBD (Inflammatory Bowel Disease) and additional indications
Counterparty: Innovo Therapeutics (South Korea); Contract date: May 12, 2026
Term: 15 years from first commercial sale or until last expiring Background IP, whichever is later
Total contract value up to KRW 662.5 billion (based on IBD indication, excluding additional indication royalties)
Upfront payment of KRW 6.5 billion (non-refundable), development milestones up to KRW 19 billion, regulatory milestones up to KRW 207 billion, sales milestones up to KRW 430 billion, plus separate royalties
Conditional contract: may be terminated if clinical trials or regulatory approvals fail; clinical supply cost settlement up to KRW 1 billion excluded
KOSPI Filing Information
Filing: Major Management Matters Related to Investment Decision (INV008(15PGDH Inhibitor) Technology Introduction Contract Execution)